PRTK · Paratek Pharmaceuticals
Acquired Company
Gurnet Point Capital and Novo Holdings completed the acquisition of Paratek Pharmaceuticals, Inc. for approximately $462 million, including the assumption of debt and a contingent value right, with Paratek stockholders receiving $2.15 per share in cash plus a CVR of $0.85 per share.
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use.
Market Cap
N/A
52 Wk Range
N/A - N/A
Previous Close
$2.23
Open
$2.23
Volume
N/A
Day Range
$2.23 - $2.23
Enterprise Value
N/A
Cash
N/A
Avg Qtr Burn
N/A
Insider Ownership
11.70%
Institutional Own.
55.08%
Qtr Updated
Sep 30th 2024